EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration

Paul Thoueille iD, Susana Alves Saldanha, Vincent Desfontaine, Katharina Kusejko iD, Perrine Courlet iD, Pascal Andre, Matthias Cavassini iD, Laurent A Decosterd iD, Thierry Buclin iD, Monia Guidi iD, Swiss HIV Cohort Study

Journal of Antimicrobial Chemotherapy · 2023

DOI: 10.1093/jac/dkad103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Paul Thoueille und 10 weiteren Autor:innen. Beteiligte Einrichtung: Service and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Laus…. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swiss HIV Cohort Study, Swiss National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tenofovir alafenamide is gradually replacing tenofovir disoproxil fumarate, both prodrugs of tenofovir, in HIV prevention and treatment. There is thus an interest in describing tenofovir pharmacokinetics (PK) and its variability in people living with HIV (PLWH) under tenofovir alafenamide in a real-life setting.

Objectives

To characterize the usual range of tenofovir exposure in PLWH receiving tenofovir alafenamide, while assessing the impact of chronic kidney disease (CKD).

Methods

We conducted a population PK analysis (NONMEM®) on 877 tenofovir and 100 tenofovir alafenamide concentrations measured in 569 PLWH. Model-based simulations allowed prediction of tenofovir trough concentrations (Cmin) in patients having various levels of renal function.

Results

Tenofovir PK was best described using a one-compartment model with linear absorption and elimination. Creatinine clearance (CLCR, estimated according to Cockcroft and Gault), age, ethnicity and potent P-glycoprotein inhibitors were statistically significantly associated with tenofovir clearance. However, only CLCR appeared clinically relevant. Model-based simulations revealed 294% and 515% increases of median tenofovir Cmin in patients with CLCR of 15–29 mL/min (CKD stage 3), and less than 15 mL/min (stage 4), respectively, compared with normal renal function (CLCR = 90–149 mL/min). Conversely, patients with augmented renal function (CLCR > 149 mL/min) had a 36% decrease of median tenofovir Cmin.

Conclusions

Kidney function markedly affects circulating tenofovir exposure after tenofovir alafenamide administration in PLWH. However, considering its rapid uptake into target cells, we suggest only a cautious increase of tenofovir alafenamide dosage intervals to 2 or 3 days only in case of moderate or severe CKD, respectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsHIV InfectionsRenal Insufficiency, ChronicHumansTenofovirAdenineAlanine

Substanzen

TenofovirAnti-HIV AgentsAdenineAlanine

Autor:innen und Institutionen

  • Service and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
  • Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Service of Infectious Diseases, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Switzerland.

ORCID-Profile: Paul Thoueille, Katharina Kusejko, Perrine Courlet, Matthias Cavassini, Laurent A Decosterd, Thierry Buclin, Monia Guidi

Förderung

  • Swiss HIV Cohort Study
  • Swiss National Science Foundation

Zitieren

APA

Thoueille, P., Alves Saldanha, S., Desfontaine, V., Kusejko, K., Courlet, P., Andre, P., Cavassini, M., Decosterd, L. A., Buclin, T., Guidi, M., & Swiss HIV Cohort Study (2023). Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad103

Vancouver

Thoueille P, Alves Saldanha S, Desfontaine V, Kusejko K, Courlet P, Andre P, et al. Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad103

BibTeX
@article{Thoueille2023,
  author = {Thoueille, Paul and Alves Saldanha, Susana and Desfontaine, Vincent and Kusejko, Katharina and Courlet, Perrine and Andre, Pascal and Cavassini, Matthias and Decosterd, Laurent A and Buclin, Thierry and Guidi, Monia and Swiss HIV Cohort Study, Swiss HIV Cohort Study},
  title = {Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  doi = {10.1093/jac/dkad103}
}
Kostenlos starten →